James Nyagwange

Kilifi, Kenya

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 30 publications

A natural experiment in Kenya reveals durable immunosuppressive effects of early childhood malaria: a longitudinal cohort study.

A natural experiment in Kenya reveals durable immunosuppressive effects of early childhood malaria: a longitudinal cohort study.

Journal: eLife
Published: July 14, 2026

Comparison of capillary microsampling and venous blood for multi-pathogen serosurveillance.

Comparison of capillary microsampling and venous blood for multi-pathogen serosurveillance.

Journal: Scientific reports
Published: March 24, 2026

Longitudinal evidence of differential pertussis antibody durability following natural infection among vaccinated children living in contrasting malaria transmission settings in coastal Kenya.

Longitudinal evidence of differential pertussis antibody durability following natural infection among vaccinated children living in contrasting malaria transmission settings in coastal Kenya.

Journal: Vaccine
Published: January 30, 2026

Longitudinal Epidemiology and Variant Dynamics of SARS-CoV-2 in Coastal Kenya (2020-2025): Clinical Features and Wave Patterns.

Longitudinal Epidemiology and Variant Dynamics of SARS-CoV-2 in Coastal Kenya (2020-2025): Clinical Features and Wave Patterns.

Journal: Open forum infectious diseases
Published: September 01, 2025

Assessing the Impact of SARS-CoV-2 Spike Mutations on Antibody Binding: A Comparative Assessment of the Wuhan and JN.1 Variants' Full-Length Spikes in a Multiplex Luminex Assay.

Assessing the Impact of SARS-CoV-2 Spike Mutations on Antibody Binding: A Comparative Assessment of the Wuhan and JN.1 Variants' Full-Length Spikes in a Multiplex Luminex Assay.

Journal: Viruses
Published: July 30, 2025

Comparative performance of the InBios SCoV-2 Detect TM IgG ELISA and the in-house KWTRP ELISA in detecting SARS-CoV-2 spike IgG antibodies in Kenyan populations.

Comparative performance of the InBios SCoV-2 Detect TM IgG ELISA and the in-house KWTRP ELISA in detecting SARS-CoV-2 spike IgG antibodies in Kenyan populations.

Journal: Wellcome open research
Published: July 25, 2025

Heart-nosed bat alphacoronaviruses use human CEACAM6 to enter cells.

Heart-nosed bat alphacoronaviruses use human CEACAM6 to enter cells.

Journal: Nature
Published: July 23, 2025

Genomic and clinical epidemiology of SARS-CoV-2 in coastal Kenya: insights into variant circulation, reinfection, and multiple lineage importations during a post-pandemic wave.

Genomic and clinical epidemiology of SARS-CoV-2 in coastal Kenya: insights into variant circulation, reinfection, and multiple lineage importations during a post-pandemic wave.

Journal: BMC global and public health
Published: April 23, 2025

Profile: The Kenya Multi-Site Serosurveillance (KEMIS) collaboration.

Profile: The Kenya Multi-Site Serosurveillance (KEMIS) collaboration.

Journal: Gates open research
Published: February 24, 2025

Kinetics of naturally induced binding and neutralising anti-SARS-CoV-2 antibody levels and potencies among SARS-CoV-2 infected Kenyans with diverse grades of COVID-19 severity: an observational study.

Kinetics of naturally induced binding and neutralising anti-SARS-CoV-2 antibody levels and potencies among SARS-CoV-2 infected Kenyans with diverse grades of COVID-19 severity: an observational study.

Journal: Wellcome open research
Published: November 26, 2024

Evaluation of population immunity against SARS-CoV-2 variants, EG.5.1, FY.4, BA.2.86, JN.1, JN.1.4, and KP.3.1.1 using samples from two health demographic surveillance systems in Kenya.

Evaluation of population immunity against SARS-CoV-2 variants, EG.5.1, FY.4, BA.2.86, JN.1, JN.1.4, and KP.3.1.1 using samples from two health demographic surveillance systems in Kenya.

Journal: BMC infectious diseases
Published: July 29, 2024

Safety and immunogenicity of ChAdOx1 nCoV-19 (AZD1222) vaccine in adults in Kenya: a phase 1/2 single-blind, randomised controlled trial.

Safety and immunogenicity of ChAdOx1 nCoV-19 (AZD1222) vaccine in adults in Kenya: a phase 1/2 single-blind, randomised controlled trial.

Journal: Wellcome open research
Published: November 22, 2023
Showing 1-12 of 30

Last Updated: 09/26/2026